Jazz Pharmaceuticals plc 4

Patrick Kennedy, a director of Jazz Pharmaceuticals plc, was awarded 1,605 restricted stock units of ordinary shares on August 5, 2026 as part of director compensation.

On August 5, 2026, Patrick Kennedy, a non-employee director of Jazz Pharmaceuticals plc, received a grant of 1,605 restricted stock units (RSUs) representing ordinary shares under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The RSUs were awarded at no cash cost (reported price $0.00) and will vest in full on July 23, 2027, subject to his continued service and certain additional conditions. Following this grant, Kennedy’s direct ownership increased to 8,307 ordinary shares (including the awarded RSUs), with the overall transaction reflecting routine director equity compensation rather than an open-market purchase or sale.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0002013944-26-000003

Alert Tier

5